Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
April 25, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
April 11, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the...
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
February 22, 2024 16:09 ET
|
Collegium Pharmaceutical, Inc.
– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – –...
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
February 08, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Provides 2024 Financial Guidance
January 03, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
– Product Revenues, Net Expected in the Range of $580.0 Million to $595.0 Million – – Adjusted Operating Expenses* Expected in the Range of $120.0 Million to $125.0 Million – – Adjusted EBITDA*...
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
November 27, 2023 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of...
Collegium Announces $25 Million Accelerated Share Repurchase Program
November 09, 2023 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium to Participate in Upcoming Investor Conferences
November 08, 2023 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Reports Third Quarter 2023 Financial Results
November 07, 2023 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Q3’23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – – Q3’23 GAAP Net Income of $20.6 Million vs. Q3’22 GAAP Net Income of $0.5 Million – – Record Q3’23 Adjusted EBITDA of $89.4 Million, Up...